Samples are going to be important when they go after patients already using binders. Not as important for new users.
So he knows exactly what he is getting into.
We have touched on AMAG in the past as a potential acquirer because of their iron replacement therapy. We now need to put them in the mix with the new addition. Still have them behind GS.
AMAG Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that focuses on maternal health, anemia, and cancer supportive care. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women with a singleton pregnancy; Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company markets Feraheme in the United States and Canada; and as Rienso in the European Union. It sells Feraheme to authorized wholesalers and specialty distributors. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Worked with GM at AMAG. Small world.
Again, why would someone leave a solid gig at AMAG to come to this "sinking ship".
I think he feels pretty good about his decision.
So it looks like we are capturing 10% of them with about 200 scripts a week. Again remember our target group right now.